infliximab-dyyb
Patients Report Satisfaction Switching From Infliximab to Biosimilars
Most patients with IBD who switch from infliximab to an infliximab biosimilar report a positive experience, ...
OCTOBER 29, 2024
Highlights of Clinical Data on Subcutaneous Infliximab: Real-World Benefits
In the final chapter of this 3-chapter webinar series, Stephen B. Hanauer, MD, discusses findings from real-world ...
APRIL 3, 2024
Highlights of Clinical Data on Subcutaneous Infliximab: Post Hoc Analyses
In the 2nd part of this 3-chapter webinar series, Stephen B. Hanauer, MD, discusses findings from post hoc analyses ...
MARCH 27, 2024
Highlights of Clinical Data on Subcutaneous Infliximab: Safety and Efficacy
In the 1st part of this 3-chapter webinar series, Stephen B. Hanauer, MD, discusses findings from the LIBERTY-CD/UC ...
MARCH 20, 2024
FDA Approves Subcutaneous Infliximab for IBD
The FDA approved Zymfentra, a subcutaenous formulation of infliximab, for the treatment of inflammatory bowel ...
OCTOBER 27, 2023
Feds to Push for More Biosimilar Competition
The FDA and the Federal Trade Commission (FTC) announced they will take further action to stem anticompetitive ...
FEBRUARY 14, 2020
